| Hint | Answer | % Correct |
|---|---|---|
| dopamine | 71%
| |
| what are the drug types used to treat depression? | SSRIs (selective serotonin reuptake inhibitors) | 69%
|
| serotonin | 64%
| |
| serotonin | 64%
| |
| what is an example of each of these drug types? | escitalopram, sertraline, etc | 51%
|
| noradrenaline | 49%
| |
| noradrenaline | 49%
| |
| SNRIs (serotonin-noradrenaline reuptake inhibitors) | 49%
| |
| control of appetite, sleep, mood, hallucinations, pain perception and vomiting | 44%
| |
| what are the main neurotransmitters of the CNS? | GABA | 44%
|
| what neurotransmitters are anxiety symptoms mediated by? | GABA | 44%
|
| what is an example of each of these drug types? | diazepam, lorazepam, etc | 40%
|
| what are the two main drug types that are used to treat anxiety? | benzodiazepines | 36%
|
| what is depression characterised by? | low mood, lack of motivation and interest, and aversion to activity | 31%
|
| venlafaxine, desvenlafaxine, etc | 29%
| |
| TCAs (tricyclic antidepressants) | 24%
| |
| MAOIs (monoamine oxidase inhibitors) | 22%
| |
| amitriptyline, amoxapine, etc | 16%
| |
| inhibits serotonin, sigma, muscarinic, NMDA and histamine receptors | 16%
| |
| what is their mechanism of action? | selectively blocks the reuptake of serotonin back into the pre-synaptic cell, meaning that free serotonin stays in the synaptic gap longer and may bind again to serotonin receptors | 16%
|
| what is their mechanism of action? | binding to allosteric site of GABA-A receptors to enhance GABA binding | 13%
|
| what is anxiety characterised by? | a feeling of dread, apprehension or uneasiness that often arises from an unknown source | 11%
|
| barbiturates | 11%
| |
| blocks the reuptake of serotonin and noradrenaline back into the pre-synaptic cell | 11%
| |
| blocks the reuptake of serotonin and noradrenaline back into the pre-synaptic cell, meaning that both neurotransmitters stay in the synaptic gap longer and may bind again to their receptors | 11%
| |
| increases arousal and alertness | 11%
| |
| what is the function of each in the CNS? | mediates majority of inhibitory post-synaptic potentials | 9%
|
| phenobarbitone, amobarbitone, etc | 9%
| |
| pirlindole, selegiline, etc | 9%
| |
| what is thought to be the pathophysiology of depression? | insufficient monoamine neurotransmitter activity | 7%
|
| what is thought to be the pathophysiology of anxiety? | involves neurochemical dysfunction (e.g. decreased GABA-ergic tone, increased cortisol expression) and/or dysfunction of the amygdala in the brain | 7%
|
| what is the aims of pharmacological treatment of depression? | restore monoamine neurotransmitter activity | 4%
|
| inhibits the activity of monoamine oxidase A and/or B, preventing the enzymes from breaking down monoamine neurotransmitters, increasing their availability | 2%
|